Derm Meets Gyn:

Daily Challenges in Vulvar Pathology

Yuna Kang, MD
University of California Los Angeles
Department of Pathology and Laboratory Medicine



Derm Meets Gyn:

Daily Challenges in Vulvar Pathology

& anogenital

Yuna Kang, MD
University of California Los Angeles
Department of Pathology and Laboratory Medicine



UCLA

NO RELEVANT DISCLOSURES

Vulvar/anogenital disease—at the intersection of gyn, GU, GI, derm



Dermatologists

Vulvar/anogenital disease



Gyn/GU/GI




BENIGN VULVAR/ANOGENITAL SKIN PATHOLOGY:


- 1) "ULCER"
- 2) "IRRITATION"
- 3) "RULE OUT CONDYLOMA"

Case 1: "Ulcer"


Case 1-1: Vulvar ulcer in a 11 year old girl --Rapid onset of bilateral vulvar ulcers



Case 1-1: Vulvar ulcer in a 11 year old girl --Rapid onset of bilateral vulvar ulcers





Case 1-1: Vulvar ulcer in a 11 year old girl --Rapid onset of bilateral vulvar ulcers






Case 1-2: Vulvar ulcer in a 47 year old woman








Case 1-2: Vulvar ulcer in a 47 year old woman





"Ulcer"

BENIGN ANOGENITAL ULCER DDX

- Infection (HSV, bacterial/fungal, syphilis etc)
- Systemic disease: Behçet disease (history of painful orogenital ulceration and ocular involvement), Crohn disease
- Drug (medication)-related eruption
- Acute genital ulceration (Lipschütz Ulcer)

Reference: 13

Case 1: Lipschütz Ulcer (acute genital ulceration)

- Diagnosis of exclusion--sexually transmitted infections, Behc_set's syndrome, extra-genital Crohn's disease, drugs eruption must be ruled out.
- Initially described in 1913 by Benjamin Lipschütz--it was thought to be a rare and likely underdiagnosed condition, but a recent studies report that it may account for up to 30% of vulvar ulcerations encountered in a clinic¹.
- Demographics: Commonly seen in younger age groups (mean age of 29 in one study¹), but reported in a wide age range including children.
- Pathogenesis? Not well studied—hypotheses include: immune complex deposition and formation of microthrombi secondary to bacterial or viral infection (EBV, mycoplasma, CMV, influenza, etc.), leading to ulcers².

Case 1: Lipschütz Ulcer (acute genital ulceration)

- **Clinical presentation:** In vulva, the lesions were more frequently found on the labia minora/vestibule.
- History: Patients commonly report non-gynecological symptoms (such as fever, respiratory symptoms) prior to presenting with the vulvar lesions, supporting possibility of association with possible infectious agents.*
- **Treatment:** The lesions are self-limiting and heal within several weeks, and only conservative measures are taken.

Case 1: Lipschütz Ulcer—COVID-19 link?


- Cases of Lipschütz ulcers are reported in association with COVID-19 infection (n=18) or vaccinations (n=33)¹. Several different types of vaccines implicated
- Vulvar ulcer usually occurs within 48–72 h following the vaccination and resolved 2-3 weeks later².

Case 1: Lipschütz Ulcer

Microscopic findings of LU:

- Non-specific superficial ulceration with granulation tissue, fibrin deposition, and a mixed inflammatory cell infiltrate.
- Vasculitis, including lymphocytic arteritis and leukocytoclastic vasculitis, have been reported.
- In EBV-associated cases, EBV may be detected by ISH or PCR.

FIGURE 4. Endarteritis obliterans, chronic active arteritis, and ulcerated mucosal lymphoid hyperplasia associated with EBV early mRNA (EBER) expression. A 40-year-old woman and RTR presented with 4month history of a persistent painful ulcer. She has a history of anogenital ulcers that improve with acyclovir therapy, unlike the present ulcer which was resistant to acyclovir therapy. Incisional biopsy of the ulcer showed a diffuse, dense lymphocytic infiltrate with coexisting fibrosis (top right and mid-panels). Scattered lymphocytes, less than 5%, expressed EBER by in situ hybridization. At the ulcer base and throughout the sampled tissue could be found arteries with panmural inflammation and fibrointimal hyperplasia (bottom mid panel) or arteries with complete occlusion of their lumens (endarteritis obliterans) (bottom left panel, elastic tissue stain).



EBV-positive mucocutaneous ulcer is in the differential diagnosis^{29,30}; the absence of a polymorphous infiltrate with atypical large lymphocytes (immunoblasts), Reed–Sternberg-like cells, and plasmacytoid apoptotic cells exclude this closely related entity showing persistent ulceration that is associated with chronic active EBV infection and immunosuppression.

UCLA

```
Case Reports > Am J Mens Health. 2023 Jul-Aug;17(4):15579883231184683.
```

doi: 10.1177/15579883231184683.

Genital Ulcer as a Complication of COVID-19 Infection: A Case Report

```
Rayka Sharifian <sup>1</sup>, Ali Mohammad Mirjalili <sup>2</sup>, Arshia Zamani Hajiabadi <sup>3</sup>
```

Affiliations + expand

PMID: 37421309 PMCID: PMC10331107 DOI: 10.1177/

Case Reports > Int J STD AIDS. 2022 May;33(6):622-624. doi: 10.1177/09564624221085726. Epub 2022 Mar 25.

A case of COVID-19-related acute genital ulceration in a male

Abdurrahman Kaya ¹, Sibel Yıldız Kaya ²

Affiliations + expand

PMID: 35337226 PMCID: PMC8960746 DOI: 10.1177/09564624221085726



Case 2: "Irritation"

TABLE

Characteristic conditions*


	Candidiasis	Lichen sclerosus	Lichen planus	VIN (vulvar intraepithelial neoplasia)	Eczema	Psoriasis
Clinical presentation			7			
Frequency (prevalence)	10–20%	0.1–3%	0.1–0.8%	Exact prevalence unknown, incidence Approx. 3/100 000 women in Germany	0.5–10%	2%
Morphological features	Red and white plaques, erosions, ulcers	- Early form: erythema, erosions - Late form: white, firm plaques, bleeding into skin, scarring, atrophy, fissures, exaggerated skin markings	- Early form: charact. whitish reticulate (Wickham) striae - Late form/erosive form: erosive erythema, scarring, extragenital involvement (e.g. oral)	Skin-colored papules and nodules, white and red plaques, acetowhite lesions (after application of 5% acetic acid), erosions (especially with differentiated VIN)	Poorly marginated erythema- tous lesions on the labia majora and labia minora, edema (acute), lichenification (chronic)	Well-demarcated, slightly scaly, erythematous red plaques, accompanying fis- sures and rhagades
Signs & symptoms	Pruritus, erythema, increased vaginal discharge (white, curd-like, no odor)	Pruritus, burning, dyspareunia	Early form: pruritus, burning, pain Late form: dyspareunia, burning, vaginal stenosis	Pruritus, burning, soreness, often asymptomatic	Pruritus, soreness	Pruritus
Diagnosis	pH value: normal (< 4.0) Lactobacilli: yes Leukocytes: increased Clue cells: none Microscopy: Pseudomycelium & blastospores	History, clinical examination, typical figure-of-8 pattern sur- rounding the vulva and anus; histological confirmation by biopsy, if required	History, clinical examination, characteristic Wickham striae, vaginal involvement, histologi- cal confirmation by biopsy	Vulvoscopy, histological confir- mation by biopsy	History, clinical examination, if necessary, patch test	Typical involvement of labia majora, characteristic non-involvement of labia minora
Management	Acute: Antifungal agent (e.g. oral fluconazole or topical clotrimazole preparations) Chronic: Following the initial treatment, fluconazole 150 mg orally 1 x/week for at least 6 months after loading dose	Initially ultrapotent glucocorticoids (GC) (topical) Life-long GC maintenance dose in reduced dose, lipid replenishment Second-line therapy: calcineurin inhibitors (off-label)	Initially ultrapotent glucocorticoids (GC) (topical) Life-long GC maintenance dose in reduced dose, lipid replenishment Second-line therapy: calcineurin inhibitors (off-label)	- Laser vaporization (standard with usual-type VIN) - Surgical excision rather with differentiated VIN (Warning: occult carcinoma) - Imiquimod 5%, topical for usual-type VIN (off-label)	Avoidance of trigger factors Glucocorticoids (topical)	Avoidance of mechanical stress and trigger factors Topical treatment as for extragenital psoriasis (typically GC/calcineurin inhibitors)


Causes of "vulvar irritation"

ONCE DYSPLASIA/MALIGNANCY IS RULED OUT...


- 1) BUGS? FUNGAL (CANDIDA/TINEA), HSV, MOLLUSCUM, ETC
- 2) IS IT LICHEN SCLEROSUS (LS)?
- 3) ECZEMATOUS/CONTACT DERMATITIS OR PSORIASIS?

Reference: 22






Case 2: 70F, vulvar itching and erythema, rule out lichen sclerosus



Case 2: 70F, vulvar itching and erythema, rule out lichen sclerosus



Causes of "vulvar irritation"

ONCE DYSPLASIA/MALIGNANCY IS RULED OUT...


1) BUGS? FUNGAL (CANDIDA/TINEA), HSV, MOLLUSCUM, ETC

2) LICHEN SCLEROSUS?

3) ECZEMATOUS/CONTACT DERMATITIS OR PSORIASIS?

Reference: 27

LS histopathology—classic features




Interface changes in the basal layer

Superficial dermal edema, sclerosis and hyalinization

B) Lichenoid inflammation=Band of lymphocyte-predominant inflammation below the sclerosis

Reference: 28

LS histopathology—when things are less classic...




CLUES TO THE DIAGNOSIS OF LS

- A) Early superficial hyalinization
- B) PAS stain highlighting early deposition of hyalinized material underneath the basement membrane and around vessels in the superficial dermis.
- C) Lymphocytes lining up along the basal layer
- D) Entrapment of lymphocytes in wiry collagen
- * Telangiectasia is often prominent and associated purpura (dermal red blood cell extravasation) and hemosiderin may be present.


•

LS histopathology—when things are less classic...



OTHER CLUES

- Follicular changes:
 - perifollicular basement membrane thickening
 - follicular plugging/ hyperkeratosis
- Vertical columns of parakeratosis ²
- Detached epidermis ²










TABLE						
Characteristic conditions*						
	Candidiasis	Lichen sclerosus	Lichen planus	VIN (vulvar intraepithelial neoplasia)	Eczema	Psoriasis
Clinical presentation			3			
Frequency (prevalence)	10–20%	0.1–3%	0.1-0.8%	Exact prevalence unknown, incidence Approx. 3/100 000 women in Germany	0.5–10%	2%
Morphological features	Red and white plaques, erosions, ulcers	- Early form: erythema, erosions - Late form: white, firm plaques, bleeding into skin, scarring, atrophy, fissures, exaggerated skin markings	- Early form: charact, whitish reticulate (Wickham) striae - Late form/erosive form: erosive erythema, scarring, extragenital involvement (e.g. oral)	Skin-colored papules and nodules, white and red plaques, acetowhite lesions (after application of 5% acetic acid), erosions (especially with differentiated VIN)	Poorly marginated erythema- tous lesions on the labia majora and labia minora, edema (acute), lichenification (chronic)	Well-demarcated, slightly scaly, erythematous red plaques, accompanying fis- sures and rhagades
Signs & symptoms	Pruritus, erythema, increased vaginal discharge (white, curd-like, no odor)	Pruritus, burning, dyspareunia	- Early form: pruritus, burning, pain - Late form: dyspareunia, burning, vaginal stenosis	Pruritus, burning, soreness, often asymptomatic	Pruritus, soreness	Pruritus
Diagnosis	pH value: normal (< 4.0) Lactobacilli: yes Leukocytes: increased Clue cells: none Microscopy: Pseudomycelium & blastospores	History, clinical examination, typical figure-of-8 pattern sur- rounding the vulva and anus; histological confirmation by biopsy, if required	History, clinical examination, characteristic Wickham striae, vaginal involvement, histologi- cal confirmation by biopsy	Vulvoscopy, histological confir- mation by biopsy	History, clinical examination; if necessary, patch test	Typical involvement of labia majora, characteristic non-involvement of labia minora
Management	Acute: Antifungal agent (e.g. oral fluconazole or topical clotrimazole preparations) Chronic: Following the initial treatment, fluconazole 150 mg orally 1 x/week for at least 6 months after loading dose	Initially ultrapotent glucocorticoids (GC) (topical) Life-long GC maintenance dose in reduced dose, lipid replenishment Second-line therapy: calcineurin inhibitors (off-label)	Initially ultrapotent glucocorticoids (GC) (topical) Life-long GC maintenance dose in reduced dose, lipid replenishment Second-line therapy: calcineurin inhibitors (off-label)	- Laser vaporization (standard with usual-type VIN) - Surgical excision rather with differentiated VIN (Warning: occult carcinoma) - Imiquimod 5%, topical for usual-type VIN (off-label)	Avoidance of trigger factors Glucocorticoids (topical)	Avoidance of mechanical stress and trigger factors Topical treatment as for extragenital psoriasis (typically GC/calcineurin inhibitors)

LP histopathology



- Hyperkeratosis and wedge-shaped Hypergranulosis
- Saw-toothing/serrated epidermis (pointed rete)
- Lichenoid (band-like) lymphocytepredominant inflammation in the superficial dermis, obscuring the basal epidermis + many necrotic keratinocytes
- Subepidermal clefting may be present

Lichen sclerosus (LS)—clinical clues



CLINICAL EXAM

- Female genital LS affects vulva, perineum, anus, genitocrural folds, buttocks and thighs.
- Lichenified, white/porcelain atrophic skin with hemorrhage and architectural changes
- "Figure of eight" involvement of vulva and anus is a common distribution. Mucosal involvement of vagina is not a typical feature (in contrast to LP).

Usually involves clitoris → labia minora/majora → perineum → perianal skin (vaginal mucosal involvement is rare)

Lichen planus—clinical clues







Fig. 10. Clinical presentation of hypertrophic lichen planus. Hypertrophic errithematous plaques of the blitareal labia majora are seen, extending into the interlabia sulci and coalescing over the anterior commissure. The labia minora are preserved but partial clitoral phimosis is present. There are no vestibular regions.

- Check for clinical history of LP: patients with vulvar LP frequently have a history of LP involving other parts of the body (i.e. oral)
- Several subtypes of LP exist (classic/hypertrophic, and erosive)
 - Erosive LP involves the vagina and may result in scarring/stricture if left untreated.

CRITERIA		LICHEN PLANUS	LICHEN SCLEROSUS
CLINICAL	Vaginal involvement	Frequent in erosive LP	Extremely rare
	Oral involvement	Frequent	Extremely rare
	Perianal involvement	Rare	Frequent








Reference:


CRITERIA		LICHEN PLANUS	LICHEN SCLEROSUS
CLINICAL	Vaginal involvement	Frequent in erosive LP	Extremely rare
	Oral involvement	Frequent	Extremely rare
	Perianal involvement	Rare	Frequent
HISTOLOGIC	Serrated epidermis/sawtoothing	Frequent	Rare
	Wedge-shaped hypergranulosis	Frequent	Rare
	Necrotic keratinocytes/Colloid bodies	Numerous	Not as numerous as LP
	Thickening of the basement membrane	Rare	Frequent
	Collagen hyalinization	Rare	Frequent
	Hemorrhage or siderophages	Rare	Frequent
	Lymphocyte entrapment by wiry fibrosis	Rare	Frequent









Case 2: 70F, vulvar itching and erythema, rule out lichen sclerosus





Case 2: 70F, vulvar itching and erythema, rule out lichen sclerosus



Clinical significance of LS

 LS has been considered to carry an increased risk of vulvar squamous cell carcinoma (SCC) lifetime risk of 2-6% for untreated/inadequately treated

With intervention, these complications may be prevented.

Therefore, use clinical and pathologic clues, and if LS is in the microscopic DDX, keep it in the DDX

Reference: 41





"Atchoum, as you may have figured out, is a cat "

Case 3: "Rule out condyloma"




Low-grade SIL (LSIL)/VIN1










CASE 3-2: Labia minora/vestibular polypoid lesions, rule out condyloma




Vestibular papillomatosis











"Rule out condyloma"

BENIGN BUMPS DDX

- Folliculitis/epidermal inclusion cyst
- Molluscum
- Verruciform xanthoma
- Vestibular papillomatosis
- Angioma/ lymphangioma (circumscriptum)
- Sebaceous hyperplasia
- Other rare entities: parasites, cloacogenic remnants, etc.

Reference: 58

TAKE HOME POINTS

- "ULCER": Acute genital ulceration is a diagnosis of exclusion, and may occur following systemic infections (i.e. EBV, COVID) & COVID vaccine.
- "IRRITATION": In "rule out LS" cases without prominent dermal sclerosis, it is helpful to correlate with site of involvement and look for the subtle clues of LS (superficial fibrosis, lymphocyte along the basal layer, follicular changes, entrapped lymphocytes in fibrotic dermis etc.)
- "RULE OUT CONDYLOMA": Think about common anogenital "benign bumps". Deeper sections may be necessary to find the diagnostic focus.



Questions or comments?